Servier and MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced a research partnership to identify and develop small activating RNA (saRNA) therapies for the treatment of neurological disorders.
MiNA Therapeutics will use its saRNA platform to identify new potential treatments to restore normal cell function in neurological disorders. Servier will be responsible for preclinical and clinical development of lead candidates and will have the rights for the commercialization of any products resulting from the collaboration.
“MiNA’s innovative approach to activate gene expression through small activating RNAs is an exciting opportunity to unlock potential for the treatment of genetically defined neurodegenerative diseases, for which there are currently limited treatment options,” said Ross Jeggo, Head of the Servier Neurology and Immuno-Inflammation Therapeutic Area. “We are delighted to welcome the MiNA team and to combine their unique approach to restoring cellular function with Servier’s focus on treating neurological diseases.”
Did you know?
In the field of neurology, Servier focuses its research on neurodegenerative diseases. Servier targets proteinopathies, characterized by abnormal accumulation of certain proteins, such as Parkinson’s disease or rare diseases such as amyotrophic lateral sclerosis.